Spots Global Cancer Trial Database for A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Official Title: A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
Study ID: NCT04866017
Conditions
Study Description
Brief Summary: The primary objective of this study is to compare progression-free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm C (Durvalumab) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in participants with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
XCancer/Centeral Care Center, Bolivar, Missouri, United States
Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
Townsville Hospital, Douglas, Queensland, Australia
Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia
Royal Hobart Hospital, Hobart, Tasmania, Australia
Cabrini Hospital, Malvern, Victoria, Australia
Gold Coast University Hospital, Gold Coast, , Australia
Hollywood Private Hospital, Perth, , Australia
Beijing Cancer Hospital, Beijing, Beijing, China
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hunan Cancer Hospital - GCP Office, Changsha, Hunan, China
Nanjing First Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University Branch Shizi, Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Jilin Cancer Hospital, Changchun, Jilin, China
The First Hospital of Jilin University, Changchun, Jilin, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
Peking University Third Hospital, Beijing, , China
Changzhou Cancer Hospital, Changzhou, , China
Jieyang People'S Hospital (Jieyang Affiliated Hospital, Sun Yat-Sen University ), Jieyang, , China
Changhua Christian Hospital, Changhua, , Taiwan
Chung Shan Medical University Hospital, Taichung, , Taiwan
Taichung Veterans General Hospital, Taichung, , Taiwan
Taipei Veterans General Hospital, Taipei, , Taiwan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
